Form 4: Protara Therapeutics Executive Zummo Sells Shares to Cover Tax Obligations
SEC Form 4
Jacqueline Zummo, Chief Scientific Operations Officer of Protara Therapeutics, sold 6,554 shares of common stock on January 21, 2025, to cover income tax obligations related to vesting restricted stock units.
Summary
- On January 21, 2025, Jacqueline Zummo, the Chief Scientific Operations Officer of Protara Therapeutics, sold 6,554 shares of the company's common stock.
- The sale was executed to satisfy income tax obligations associated with the vesting of Restricted Stock Unit Awards granted on January 19, 2023, and January 19, 2024.
- The shares were sold at a price of $4.76 per share.
- Following the transaction, Zummo directly owns 95,585 shares of Protara Therapeutics common stock.
Sentiment
Score: 5
Explanation: The document reflects a routine transaction (selling shares to cover taxes) and doesn't inherently indicate positive or negative sentiment regarding the company's performance.
Industry Context
Form 4 filings are a routine part of the US stock market, providing transparency into the transactions of company insiders. This transaction is a common occurrence where executives sell shares to cover tax obligations related to stock awards.
Stakeholder Impact
- The sale of shares by an executive could have a minor impact on shareholder sentiment, but is unlikely to be significant given the reason for the sale.
Key Dates
| Date | Description |
|---|---|
| 01/19/2023 | Date of Restricted Stock Unit Awards granted to the Reporting Person |
| 01/19/2024 | Date of Restricted Stock Unit Awards granted to the Reporting Person |
| 01/21/2025 | Date of transaction (stock sale) |
| 01/23/2025 | Date of signature on the Form 4 filing |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.